Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akari Therapeutics (AKTX) Notes Payables (2012 - 2026)

Akari Therapeutics recorded quarterly Notes Payables of $49000.0 in Q1 2026, down 39.51% quarter-over-quarter from $81000.0 in Q4 2025, and down 78.51% year-over-year from $228000.0 in Q1 2025.

Akari Therapeutics' Notes Payables history runs 4 years deep, the most recent figure standing at $49000.0 for Q1 2026.

  • In Q1 2026, Notes Payables fell 78.51% year-over-year to $49000.0; the TTM figure through Mar 2026 stood at $49000.0 (down 78.51% YoY), while the FY2025 annual figure was $81000.0, down 87.71% from the prior year.
  • Notes Payables came in at $49000.0 for Q1 2026 at Akari Therapeutics, down from $81000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $659000.0 in Q4 2024 to a low of $49000.0 in Q1 2026.
  • A 3-year average of $232333.3 and a median of $188500.0 in 2025 frame the typical range for Notes Payables.
  • Across the five-year window, Notes Payables tumbled 87.71% in 2025 and plunged 78.51% in 2026, its largest moves.
  • Akari Therapeutics' Notes Payables stood at $659000.0 in 2024, then sank by 87.71% to $81000.0 in 2025, then tumbled by 39.51% to $49000.0 in 2026.
  • According to Business Quant data, Notes Payables over the past three periods registered $49000.0, $81000.0, and $198000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 49,000.00
Dec 31, 2025 81,000.00
Sep 30, 2025 198,000.00
Jun 30, 2025 179,000.00
Mar 31, 2025 228,000.00
Dec 31, 2024 659,000.00
Dec 31, 2012 898,000.00